Skip to main content

The independent medical news service

Prostate cancer

11-01-2022 | Oncology | News | Article

Better outcomes with radiotherapy for Black versus White prostate cancer patients

Black men with localized prostate cancer fare better than their White counterparts after definitive radiotherapy, suggests a meta-analysis.

05-01-2022 | Oncology | News | Article

HRQoL data reported for ENZAMET trial of enzalutamide in metastatic HSPC

The addition of enzalutamide rather than a standard nonsteroidal anti-androgen to testosterone suppression is associated with worsening of some health-related quality of life function and symptom scores in men with metastatic hormone-sensitive prostate cancer, report the ENZAMET researchers.

20-12-2021 | Oncology | News | Article

Sexual function recovery post-prostatectomy varies across patients, surgeons

Recovery of sexual function varies widely following radical prostatectomy at both the patient and surgeon level, but is not associated with surgeon case volume, US researchers report.

30-11-2021 | Oncology | News | Article

Metformin, statins may help prevent advanced prostate cancer deaths

Postdiagnostic metformin or statin use may reduce the risk for death among people with advanced prostate cancer, suggests an analysis of US Veteran Health Administration data.

23-11-2021 | Oncology | News | Article

Treatment-related regret common in localized prostate cancer patients

Around 10% of men with localized prostate cancer experience treatment-related regret but this rate varies by treatment modality and is mediated by posttreatment functional outcomes and patient expectations, study findings indicate.

16-11-2021 | Oncology | News | Article

Guideline change triggers increased PSA screening

Rates of prostate-specific antigen testing have increased significantly since 2017, following the publication of guidelines reversing a previous recommendation against routine prostate cancer screening in young men, US researchers report.

27-10-2021 | Oncology | News | Article

Pathogenic mismatch repair variants IMPACT prostate cancer incidence

Men who carry germline mismatch repair pathogenic variants in the MSH2 and MSH6 genes, typically associated with Lynch syndrome, have a significantly higher incidence of prostate cancer than noncarriers, show early data from the IMPACT study.

24-09-2021 | Oncology | News | Article

Combining LuPSMA with pembrolizumab ‘promising’ for mCRPC

Results of the PRINCE trial point to the potential of LuPSMA plus pembrolizumab for the treatment of metastatic castration-resistant prostate cancer with high expression of PSMA.

20-09-2021 | Oncology | News | Article

STAMPEDE heralds ‘practice change’ for high-risk nonmetastatic prostate cancer

Supplementing androgen deprivation therapy with 2 years of an abiraterone acetate-based regimen significantly boosts the survival of men with high-risk nonmetastatic prostate cancer, show STAMPEDE results.

20-09-2021 | Oncology | News | Article

PEACE-1: Upfront triplet therapy gives OS advantage to men with mCSPC

The addition of abiraterone acetate to standard therapy with docetaxel plus androgen deprivation therapy significantly improves the overall survival of patients with de novo metastatic castration-sensitive prostate cancer, report the PEACE-1 investigators.

19-09-2021 | Oncology | News | Article

ARCHES reports enzalutamide OS benefit in men with mCSPC

The final analysis of the ARCHES trial has demonstrated a significant overall survival boost with the addition of enzalutamide instead of placebo to androgen deprivation therapy in the metastatic castration-sensitive prostate cancer setting.

08-09-2021 | Oncology | News | Article

PRONOUCE fails to resolve CV safety questions for GnRH antagonists, agonists

Slow recruitment and low event rates have led to early termination of the PRONOUNCE trial, which hoped to determine the relative cardiovascular safety of gonadotropin-releasing hormone antagonists and agonists in men with prostate cancer.

06-09-2021 | Oncology | News | Article

Significant declines in cancer diagnoses during first year of COVID-19 pandemic

The number of new cancer diagnoses during the first year of the COVID-19 pandemic was lower than in the prepandemic period, report US researchers.

31-08-2021 | Oncology | News | Article

Antitumor activity of talazoparib demonstrated in pretreated mCRPC

Phase 2 study data show that the PARP inhibitor talazoparib has antitumor activity in men with heavily pretreated metastatic castration-resistant prostate cancer bearing DNA damage response alterations in genes associated with homologous recombination repair.

25-08-2021 | Oncology | News | Article

ERASE trial demonstrates beneficial effects of HIIT in men with prostate cancer

Men with localized prostate cancer undergoing active surveillance who follow a high-intensity interval training regimen can expect improvements in cardiorespiratory fitness and indicators of biochemical progression, early findings indicate.

18-08-2021 | Oncology | News | Article

Novel blood-based algorithm outperforms PSA for prostate cancer screening

The Stockholm3 risk prediction tool performs at least as well as prostate-specific antigen screening for the detection of clinically significant prostate cancer, research suggests.

13-08-2021 | Oncology | News | Article

Active surveillance ‘an appropriate option’ for some African–American prostate cancer patients

A US study has found no significant difference in outcomes between African–American and White men undergoing active surveillance for intermediate-risk prostate cancer.

11-08-2021 | Oncology | News | Article

Adding bone resorption inhibitors to abiraterone may prolong mCRPC survival

The addition of bone resorption inhibitors to abiraterone acetate plus prednisone is associated with improved survival outcomes in patients with metastatic castration-resistant prostate cancer and bone metastases, especially if they have high-volume disease, researchers report.

02-08-2021 | Oncology | News | Article

Second-generation androgen receptor inhibitors supported for older nonmetastatic CRPC patients

Nonmetastatic castration-resistant prostate cancer patients aged 80 years and older benefit from treatment with second-generation androgen receptor inhibitors, suggests a pooled analysis of three trials.

26-07-2021 | Oncology | News | Article

Care of Black prostate cancer patients disproportionately affected during COVID-19

Black men with nonmetastatic prostate cancer were significantly less likely than their White counterparts to undergo prostatectomy during the initial wave of the COVID-19 pandemic, reports a US research team.

Image Credits